NCT06761274 Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma
| NCT ID | NCT06761274 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Hodgkin Lymphoma in Remission |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2022-11-03 |
| Primary Completion | 2025-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2022-11-03 with a primary completion date of 2025-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Study design: It is a monocentric and exploratory study, experimental on human tissues in vitro which involves the analysis of peripheral blood in patients with Hodgkin's lymphomas with the following characteristics: * in complete remission for at least two years after first-line therapy with stage IIb, III or IV at onset (Ann Arbor classification). * newly diagnosed (stage IIb, III or IV, Ann Arbor Classification).
Eligibility Criteria
Inclusion Criteria: * hodgkin lymphoma stage II b, III or IV at onset in remission for at least two years after the first line of therapy for lymphoma * Newly diagnosed histologically confirmed stage II b, III or IV patients who require first-line therapy * Patients of both sexes aged ≥ 18 years at enrollment * Signature of informed consent Exclusion Criteria: * Concomitant second neoplasm
Contact & Investigator
Pier Luigi Zinzani, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06761274 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hodgkin Lymphoma in Remission. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06761274 currently recruiting?
Yes, NCT06761274 is actively recruiting participants. Contact the research team at pierluigi.zinzani@unibo.it for enrollment information.
Where is the NCT06761274 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06761274 clinical trial?
NCT06761274 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Pier Luigi Zinzani, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 200 participants.